Synergistic effect of Abraxane that combines human IL15 fused with an albumin‐binding domain on murine models of pancreatic ductal adenocarcinoma

Nab‐paclitaxel (Abraxane), which is a nanoparticle form of albumin‐bound paclitaxel, is one of the standard chemotherapies for pancreatic ductal adenocarcinoma (PDAC). This study determined the effect of Abraxane in combination with a fusion protein, hIL15‐ABD, on subcutaneous Panc02 and orthotopic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Fei‐Ting, Tsai, Chang Liang, Chiang, I‐Tsang, Lan, Keng‐Hsueh, Yueh, Po‐Fu, Liang, Wen‐Yi, Lin, Chi‐Shuo, Chao, Yee, Lan, Keng‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980892/
https://www.ncbi.nlm.nih.gov/pubmed/35174623
http://dx.doi.org/10.1111/jcmm.17220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980892/
https://www.ncbi.nlm.nih.gov/pubmed/35174623
http://dx.doi.org/10.1111/jcmm.17220

Ejemplares similares